FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W630169466> ?p ?o ?g. }

• W630169466 endingPage "5902" @default.
• W630169466 startingPage "5902" @default.
• W630169466 abstract "Abstract Background: According to current data B-cell lymphoma unclassified (BCLU), intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma represents a highly aggressive type of lymphoma with dramatically bad response for chemotherapy. Cases with translocation of two genes (MYC and BCL2 or BCL6) are divided into double-hit lymphomas (DHL). We need to estimate risk factors to intensify treatment and manage indications for autologous stem cell transplantation (auto-SCT) according to individual characteristics. Aim: To evaluate results of BCLU treatment according to LB-M-04±R protocol in adults younger than 60 years old and CHOP-like regimens in elderly patients (≥60 years old) with auto-SCT in high risk patients group. Patients and Methods: 21 pts observed in National Research Center for Hematology (Moscow) between 2004 and 2014 years were included in a current study. All of them were convenient to BCLU diagnosis criteria according to WHO classification of hematological malignancies (2008). Genetic analysis included: standard karyotyping in 7 pts (6 – lymph nodes samples, 1 sample of cerebrospinal fluid). FISH analysis was performed in 21 pts (in 7 cases on tumor cells; on imprints of tumor in 4 cases, on histologic slides from paraffin blocks - in 10 cases). Taking into account heterogeneity of a common group we divided all pts into 2 subgroups: DHL and non-DHL cases (7 vs. 14 respectively). Pts younger than 60 years old (17 pts) were treated according to LB-M-04±R protocol which included A-C-A-C courses. Course A consisted from dexamethasone 10 mg/m2 i.v. 1-5 ds, methotrexate 1500 mg/m2 12-hours infusion 1st d, ifosfamide 800 mg/m2 1-5 ds, vincristine 1 mg/m2 1st d, doxorubicine 50 mg/m2 3rd d, cytarabine 150 mg/m2 4-5 ds, etoposide 100 mg/m2 4-5 ds; course C included dexamethasone 10 mg/m2 i.v. 1-5 ds, methotrexate 1500 mg/m2 12-hours infusion 1st d, vinblastine 5 mg/m2 1st d, cytarabine 2000 mg/m2 twice a day 2-3 ds, etoposide 150 mg/m2 3-5 ds. Rituximab were indicated before chemotherapy in dosage 375 mg/m2. CNS prophylaxis was made by intrathecal administration of prednisolone 30 mg, cytarabine 30 mg, methotrexate 15 mg in 1st day of each course. When complete remission (CR) was achieved after 2 courses, treatment lasted 4 courses. When tumor regression was diagnosed after 4 courses, treatment continued till 6 courses. 4 pts ˃60 years were managed by CHOP-like regimens ±R. We performed auto-SCT in non-DHL group with signs of poor prognosis (bone marrow involvement, multiple extranodal sites, CR after 6 courses) and in DHL when CR had been achieved after 4 courses. Pts with DHL after auto-SCT received 2 R-EPOCH courses more. As a conditional regimen BEAM was used. An overall survival (OS) as a primary endpoint and event-free survival (EFS) were assessed with using the Kaplan-Meier method (with log-rank test) to estimate an efficacy of treatment. Statistical analysis was performed with SAS 9.3 (SAS Institute Inc. Cary, NC). Results: Studying group included 9 males and 12 females. Comparing pts according DH and non-DH status, DHL group (n=7) consisted of 2 males and 5 females, median age 48 years (30-74), ECOG status was 2.6 (95%CI 1.3-3.9) and non-DH group consisted of 7 male and 7 female, median age was 46 (23-76), ECOG status was 2.4 (95%CI 1.8-3.1). DHL pts had stage II of lymphoma according to Ann-Arbor classification in 1 case, III in 1 case, IV in 5 cases. Non-DHL pts had stage II of lymphoma in 2 cases and IV in 12 cases. Bone marrow involvement was revealed in 2 cases in DHL group and in 5 cases in non-DHL group. More than 1 extranodal site took place in 3 cases of DHL and 8 cases of non-DHL. Survival rates of groups were comparable because they were not significantly different of these characteristics. The 2-year OS and EFS rates were less for DHL pts compared with non-DHL pts: OS: 43 vs. 75%, P=0.24 and EFS: 29 vs. 66%, P=0.09 respectively (Figures 1and 2). Auto-SCT was performed in 2 pts with DHL treated by LB-M-04±R protocol (both pts still be alive) and in 3 pts with non-DHL (1 pt treated by LB-M-04±R and 1 treated by CHOP-like regimen+R are alive in CR and 1 pt treated by LB-M-04±R protocol developed a relapse). Conclusions: Low OS and EFS in BCLU group are caused particularly by DHL cases. We need to enlarge an observation group to confirm benefits of auto-SCT in BCLU pts with signs of poor prognosis. Figure 1 Figure 1. Figure 2 Figure 2. Disclosures No relevant conflicts of interest to declare." @default.
• W630169466 created "2016-06-24" @default.
• W630169466 creator A5006140546 @default.
• W630169466 creator A5009478102 @default.
• W630169466 creator A5015768274 @default.
• W630169466 creator A5017815439 @default.
• W630169466 creator A5025177149 @default.
• W630169466 creator A5033648316 @default.
• W630169466 creator A5043454332 @default.
• W630169466 creator A5044831993 @default.
• W630169466 creator A5046804186 @default.
• W630169466 creator A5060256137 @default.
• W630169466 creator A5063511988 @default.
• W630169466 creator A5064127740 @default.
• W630169466 creator A5071839937 @default.
• W630169466 creator A5077089081 @default.
• W630169466 date "2014-12-06" @default.
• W630169466 modified "2023-10-18" @default.
• W630169466 title "B-Cell Lymphoma Unclassified, Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma: A Single Center Experience of Intensive Chemotherapy with and without Auto-SCT" @default.
• W630169466 doi "https://doi.org/10.1182/blood.v124.21.5902.5902" @default.
• W630169466 hasPublicationYear "2014" @default.
• W630169466 type Work @default.
• W630169466 sameAs 630169466 @default.
• W630169466 citedByCount "0" @default.
• W630169466 crossrefType "journal-article" @default.
• W630169466 hasAuthorship W630169466A5006140546 @default.
• W630169466 hasAuthorship W630169466A5009478102 @default.
• W630169466 hasAuthorship W630169466A5015768274 @default.
• W630169466 hasAuthorship W630169466A5017815439 @default.
• W630169466 hasAuthorship W630169466A5025177149 @default.
• W630169466 hasAuthorship W630169466A5033648316 @default.
• W630169466 hasAuthorship W630169466A5043454332 @default.
• W630169466 hasAuthorship W630169466A5044831993 @default.
• W630169466 hasAuthorship W630169466A5046804186 @default.
• W630169466 hasAuthorship W630169466A5060256137 @default.
• W630169466 hasAuthorship W630169466A5063511988 @default.
• W630169466 hasAuthorship W630169466A5064127740 @default.
• W630169466 hasAuthorship W630169466A5071839937 @default.
• W630169466 hasAuthorship W630169466A5077089081 @default.
• W630169466 hasConcept C126322002 @default.
• W630169466 hasConcept C143998085 @default.
• W630169466 hasConcept C159654299 @default.
• W630169466 hasConcept C194409129 @default.
• W630169466 hasConcept C203014093 @default.
• W630169466 hasConcept C2776694085 @default.
• W630169466 hasConcept C2777537477 @default.
• W630169466 hasConcept C2778336483 @default.
• W630169466 hasConcept C2778453870 @default.
• W630169466 hasConcept C2778559949 @default.
• W630169466 hasConcept C2778913318 @default.
• W630169466 hasConcept C2779050716 @default.
• W630169466 hasConcept C2779338263 @default.
• W630169466 hasConcept C2779725641 @default.
• W630169466 hasConcept C2780073493 @default.
• W630169466 hasConcept C2780653079 @default.
• W630169466 hasConcept C2781214270 @default.
• W630169466 hasConcept C2911091166 @default.
• W630169466 hasConcept C71924100 @default.
• W630169466 hasConcept C90924648 @default.
• W630169466 hasConcept C96926380 @default.
• W630169466 hasConceptScore W630169466C126322002 @default.
• W630169466 hasConceptScore W630169466C143998085 @default.
• W630169466 hasConceptScore W630169466C159654299 @default.
• W630169466 hasConceptScore W630169466C194409129 @default.
• W630169466 hasConceptScore W630169466C203014093 @default.
• W630169466 hasConceptScore W630169466C2776694085 @default.
• W630169466 hasConceptScore W630169466C2777537477 @default.
• W630169466 hasConceptScore W630169466C2778336483 @default.
• W630169466 hasConceptScore W630169466C2778453870 @default.
• W630169466 hasConceptScore W630169466C2778559949 @default.
• W630169466 hasConceptScore W630169466C2778913318 @default.
• W630169466 hasConceptScore W630169466C2779050716 @default.
• W630169466 hasConceptScore W630169466C2779338263 @default.
• W630169466 hasConceptScore W630169466C2779725641 @default.
• W630169466 hasConceptScore W630169466C2780073493 @default.
• W630169466 hasConceptScore W630169466C2780653079 @default.
• W630169466 hasConceptScore W630169466C2781214270 @default.
• W630169466 hasConceptScore W630169466C2911091166 @default.
• W630169466 hasConceptScore W630169466C71924100 @default.
• W630169466 hasConceptScore W630169466C90924648 @default.
• W630169466 hasConceptScore W630169466C96926380 @default.
• W630169466 hasIssue "21" @default.
• W630169466 hasLocation W6301694661 @default.
• W630169466 hasOpenAccess W630169466 @default.
• W630169466 hasPrimaryLocation W6301694661 @default.
• W630169466 hasRelatedWork W1971815003 @default.
• W630169466 hasRelatedWork W2022239117 @default.
• W630169466 hasRelatedWork W2073532400 @default.
• W630169466 hasRelatedWork W2073966063 @default.
• W630169466 hasRelatedWork W2336758500 @default.
• W630169466 hasRelatedWork W2346801000 @default.
• W630169466 hasRelatedWork W2524367213 @default.
• W630169466 hasRelatedWork W3014062383 @default.
• W630169466 hasRelatedWork W3127262273 @default.
• W630169466 hasRelatedWork W630169466 @default.
• W630169466 hasVolume "124" @default.
• W630169466 isParatext "false" @default.
• W630169466 isRetracted "false" @default.

• next